Goldman Sachs analyst Andrea Tan initiated coverage of Day One Biopharmaceuticals with a Buy rating and $45 price target. Day One is a clinical stage biotechnology company developing tovorafenib for pediatric low-grade glioma, the most common childhood brain tumor, Tan tells investors in a research note. The analyst is positive into the upcoming Phase 2 FIREFLY-1 data in Q1 of 2023 to confirm tovorafenib’s "best-in-class profile."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DAWN:
- Day One Biopharmaceuticals initiated with a Buy, $34 price target at BofA
- Day One Biopharmaceuticals initiated with a Buy at BofA
- Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
- Day One Biopharmaceuticals reports Q3 EPS (53c), consensus (53c)
